• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » A New Treatment for Bipolar Depression

A New Treatment for Bipolar Depression

August 1, 2019
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
On May 28, 2019, cariprazine (Vraylar) became the fourth atypical antipsychotic to receive FDA approval for bipolar depression. The approval was based on two randomized controlled trials involving 1,051 patients and lasting 6–8 weeks. These studies grouped patients into fixed doses from 0.75–3 mg/day. The sweet spot seems to be 1.5 mg/day, which was more effective than the 0.75 mg dose and about equal to the 3 mg. There was a trend toward greater efficacy with the 3 mg dose, but also toward more adverse effects (Earley W et al, Am J Psych 2019;176:439–448; Durgam S et al, Am J Psych 2016;173:271–281).

Among the atypicals, only cariprazine and quetiapine are approved for both the manic and depressed phases of the illness. The other two atypicals for bipolar depression have either never been studied in mania (lurasidone) or contain an antidepressant that could make mania worse (olanzapine-fluoxetine combination).

Like aripiprazole (Abilify) and brexpiprazole (Rexulti), cariprazine is a partial agonist at D2 and D3 dopamine receptors, but only cariprazine is selective for D3. This is important because the D3 receptor is involved in motivation and pleasure, the so-called “hedonic drive.” Cariprazine acts as an agonist at D3 when dopamine levels are low, and an antagonist when they are high.

So far, this unique mechanism has not translated into unique efficacy for cariprazine, which has a number needed to treat comparable to that of the other atypical antipsychotics. Instead, tolerability is likely to drive the choice in this class. Cariprazine and lurasidone are more likely to cause akathisia and nausea, while quetiapine and the olanzapine-fluoxetine (OFC) combo carry greater risks of sedation, weight gain, and metabolic problems.

To prevent akathisia, I titrate cariprazine slowly, starting at 1.5 mg every other day and raising to the target dose of 1.5 mg daily after a week. Cariprazine is only available as a capsule, and the smallest size is 1.5 mg, but it has a long half-life of 2–4 days, so dosing every other day can effectively achieve a lower dose.

Cariprazine and lurasidone are brand-only, and in my experience about half of the insurers require prior authorization for these otherwise unaffordable medicines. Quetiapine and the OFC combo are both generic, but some insurers do not cover the OFC combo because the two ingredients are usually cheaper when prescribed separately.

Table: Atypical Antipsychotics With FDA Approval in Bipolar Depression

Table: Atypical Antipsychotics With FDA Approval in Bipolar Depression

Click for full-size PDF.
General Psychiatry
KEYWORDS antipsychotics atypical-antipsychotics bipolar-depression bipolar_disorder depression news_of_note pharmacology psychopharmacology
    www.thecarlatreport.com
    Issue Date: August 1, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Side Effects Part II, TCPR, August 2019
    A New Treatment for Bipolar Depression
    Another Black Eye for Prazosin in PTSD?
    l-Methylfolate for Depression: Costly Mistake or Good Thinking?
    Medication Side Effects Part II: Weight Gain, Akathisia, Hair Loss, and Orthostasis
    DOWNLOAD NOW
    Featured Book
    • MFB6eCover.jpg

      Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

      Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto22709844.jpg
      General Psychiatry

      Psychopharm Commandment #10: Don’t Fear these Meds

      Surprising health benefits of our riskiest meds: Lithium, quetiapine, and clozapine.

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.